Novo Nordisk Partners With JDRF In Type 1 Diabetes Push
This article was originally published in The Pink Sheet Daily
Novo Nordisk will conduct early research around the underlying autoimmune process central to type 1 diabetes in a partnership with JDRF; the company simultaneously opened its Type 1 Diabetes R&D Center in Seattle.
You may also be interested in...
JDRF will provide milestone-based financial support toward preclinical proof of concept for a tolerogenic vaccine candidate.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.